|
17 Jan 2018 |
First Patient Dosed in a Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)
|
|
16 Jan 2018 |
Batavia Biosciences Teams Up with International Consortium to Support Polio Eradication
|
|
13 Jan 2018 |
GSK receives FDA approval for expanded indication for FLUARIX® QUADRIVALENT (Influenza Vaccine) for persons 6 months and older
|
|
09 Jan 2018 |
Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2
|
|
04 Jan 2018 |
Targovax announces that ONCOS-102 generates immune activation in checkpoint inhibitor refractory melanoma patients
|
|
03 Jan 2018 |
Basilea reports start of clinical phase 1 study in collaboration with the U.S. Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
|
|
23 Dec 2017 |
Altimmune Announces Positive Initial Data from Its HepTcell Phase 1 Study
|
|
21 Dec 2017 |
AIVITA Biomedical Announces First Patient Enrolled in Phase II Clinical Trial for Late-Stage Ovarian Cancer
|
|
19 Dec 2017 |
VBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B Vaccine
|
|
18 Dec 2017 |
60° Pharmaceuticals (60P) Submits New Drug Application to US FDA for Antimalarial Drug Tafenoquine
|
|
18 Dec 2017 |
Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer
|
|
13 Dec 2017 |
TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense
|
|
12 Dec 2017 |
Aduro Biotech Provides Update on CRS-207 Programs
|
|
11 Dec 2017 |
Altimmune Submits Investigational New Drug Application for NasoShield in Preparation for its Phase 1 Trial
|
|
07 Dec 2017 |
Aptinyx Granted Fast Track Designation, Initiates Phase 1 for Second Clinical Candidate, NYX-783, in Post-Traumatic Stress Disorder
|
|
07 Dec 2017 |
Vertex Announces Positive Results from Open-Label Phase 3 Study of KALYDECO(R) (ivacaftor) in Children with Cystic Fibrosis Ages 1 to 2 Years
|
|
06 Dec 2017 |
New data supports the safety and efficacy of GSK’s Shingrix in preventing shingles in autologous haematopoietic stem cell transplant patients
|
|
05 Dec 2017 |
100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression
|
|
05 Dec 2017 |
ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor
|
|
05 Dec 2017 |
Immunovaccine Announces Positive Clinical Data from Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer
|
|
04 Dec 2017 |
Ovid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual Meeting
|
|
04 Dec 2017 |
Sanofi ends development of Clostridium difficile vaccine
|
|
29 Nov 2017 |
Sanofi updates information on dengue vaccine
|
|
28 Nov 2017 |
Takeda Initiates Phase 1 Clinical Trial of Zika Vaccine Candidate
|
|
28 Nov 2017 |
SOTIO Broadens Its Phase II Clinical Trial Program in Ovarian Cancer
|
